CBD OIL FOR DRUG AND NICOTINE ADDICTION
Cbd Oil can reduce some aspects of drug and nicotine withdrawal in dependent cigarette smokers and opioid dependent addicts.
Unfortunately, the last several years have seen a HUGE uptick in both opioid addiction and overdose. The death rate for opioids has increased so significantly in such a short time, that it is considered by many to be at crisis levels.
The National Institute on Drug Abuse, a division of the National Institutes of Health, has updated their website to reflect recent NIDA research on the effects of medical cannabis legalization on prescription opioid use outcomes.
The preliminary figures from the National Center for Health Statistics suggest that there were more than 64,000 drug overdose deaths in 2016. And in a shocking — but not quite surprising — reveal, synthetic opioids like fentanyl overtook both heroin and prescription painkillers in terms of overdose deaths.
The American Society of Disease Medicine characterizes addiction by a subject’s “inability to consistently abstain, impairment in behavioral control, craving, diminished recognition of significant problems with one’s behaviors and interpersonal relationships, and a dysfunctional emotional response. Like other chronic diseases, addiction often involves cycles of relapse and remission. Without treatment or engagement in recovery activities, addiction is progressive and can result in disability or premature death.”
Nicotine cravings alleviated by CBD
Similar findings were observed in a study carried out by University College London, in which cigarette smokers were given an inhaler containing CBD. 24 smokers were recruited and split into two groups: the CBD and the placebo. Both groups were encouraged to use their inhaler whenever they felt the urge to smoke a cigarette. The group using the CBD inhaler found that they smoked 40% less cigarettes, compared to the placebo group where there was no change.
According to the CDC, “The United States is in the midst of an opioid overdose epidemic. The epidemic is increasing at an alarming rate every year. And nearly half of all opioid overdose deaths involve a prescription opioid.” As they state, these deaths have increased partly because of a large increased in prescribed painkillers, and also because of the increase in cheap street heroin supplies.
Cannabidiol (CBD), is a cannabinoid in the hemp plant that may show promise in opioid remediation. THC has been well documented to enhance sensitivity to other drugs, a staple of the “gateway drug” theory. However, cannabidiol acts in the opposite way.7 From clinical studies involving rats, it appears to have a very low abuse potential and to inhibit drug-seeking behavior. Researchers have found that CBD has a longer drawn out effect up to two weeks after administration.
Methadone must be administered daily to stop drug seeking behavior in the patient. This study was an animal study, and it may have issues translating to a human context. But it does suggest that there is much hope in using CBD oil to help with withdrawal from opiates.
CBD repairs damage caused to the brain by addiction
Serious addiction ravages the body, but also causes long term neurodegeneration, associated with the over-activation of glutamate receptors resulting in a progressive loss of neurons.
CBD has been patented by the US Federal government as a neuroprotectant due to its powerful antioxidant and anti-inflammatory properties. Its ability to inhibit glutamate transmission also makes it of particular interest in combatting the damage caused by alcohol or drug related neurotoxicity.
RECENT STUDIES ON CANNABIS’ EFFECT ON HEROIN ADDICTIO
- THC-based medication reduced the severity of opioid withdrawals.
The effects of dronabinol during detoxification and the initiation of treatment with extended release naltrexone.
- Bachhuber, M.A., Saloner, B., Cunningham, C.O., and Barry, C.L. (2014). Medical Cannabis Laws and Opioid Analgesic Overdose Mortality in the United States, 1999–2010. JAMA Internal Medicine, 174(10), 1668–1673. Retrieved from https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4392651/.
- Bisaga, A., Sullivan, M.A., Glass, A., Mishlen, K., Pavlicova, M., Haney, M., Raby, W.N., Levin, F.R., Carpenter, K.M., Mariani, J.J., and Nunes, E.V. (2015, September 1). The effects of dronabinol during detoxification and the initiation of treatment with extended release naltrexone. Drug and Alcohol Dependence, 154, 38-45. Retrieved from https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4536087/.
- DrugFacts: Heroin. (2014, October). National Institute on Drug Abuse. Retrieved from http://www.drugabuse.gov/publications/drugfacts/heroin.
- Heroin Addiction. (n.d.). Addictions.com. Retrieved from http://www.addictions.com/heroin/.
- Lucas, P., Reiman, A., Earleywine, M., McGowan, S.K., Oleson, M., Coward, M.P. and Thomas, B. (2012). Cannabis as a substitute for alcohol and other drugs: A dispensary-based survey of substitution effect in Canadian medical cannabis patients. Addiction Research and Theory, Early Online, 1-8. Retrieved from http://www.tandfonline.com/doi/full/10.3109/16066359.2012.733465?needAccess=true.
- Maldonado, R., Valverde, O., and Berrendero, F. (2006, April). Involvement of the endocannabinoid system in drug addiction. Trends in Neurosciences, 29(4), 225-32. Retrieved from http://www.cell.com/trends/neurosciences/abstract/S0166-2236(06)00025-7?_returnURL=http%3A%2F%2Flinkinghub.elsevier.com%2Fretrieve%2Fpii%2FS0166223606000257%3Fshowall%3Dtrue.
- Morel, L.J., Giros, B., and Dauge, V. (2009, October). Adolescent exposure to chronic delta-9-tetrahydrocannabinol blocks opiate dependence in maternally deprived rats. Neuropsychopharmacology, 34(11), 2469-76. Retrieved from http://www.nature.com/npp/journal/v34/n11/full/npp200970a.html.
- Reiman, A. (2009). Cannabis as a substitute for alcohol and other drugs. Harm Reduction Journal, 6, 35. Retrieved from https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2795734/.
- Valverde, O., Noble, F., Beslot, F., Dauge, V., Fournie-Zaluski, M.C., and Roques, B.P. (2001, May). Delta9-tetrahydrocannabinol releases and facilitates the effects of endogenous enkephalins: reduction in morphine withdrawal syndrome without change in rewarding effect. European Journal of Neuroscience, (13)9, 1816-24. Retrieved from http://onlinelibrary.wiley.com/wol1/doi/10.1046/j.0953-816x.2001.01558.x/full.
- Walsh, Z., Gonzalez, R., Crosby, K., S Thiessmen, M., Carroll, C., and Bonn-Miller, M.O. (2016, October 12). Medical cannabis and mental health: A guided systematic review. Clinical Psychology Review, 51, 15-29. Retrieved from http://www.sciencedirect.com/science/article/pii/S0272735816300939.